US8697664B2ActiveUtilityA1

Targeted binding agents directed to PDGRF-alpha and uses thereof

60
Assignee: LAING NAOMIPriority: Aug 3, 2006Filed: Feb 18, 2010Granted: Apr 15, 2014
Est. expiryAug 3, 2026(~0.1 yrs left)· nominal 20-yr term from priority
Inventors:Naomi LaingJaspal Singh KangIan FoltzGadi Gazit-BornsteinXiao-Dang YangSue A. CartlidgeDavid Charles Blakey
A61P 43/00A61P 37/02A61P 35/00A61K 2039/505C07K 2317/76C07K 2317/21C07K 2317/73C07K 2317/56C07K 2317/92C07K 16/2863A61K 39/395C07K 16/28
60
PatentIndex Score
1
Cited by
40
References
23
Claims

Abstract

Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. An isolated nucleic acid molecule encoding both a variable light chain and a variable heavy chain of an antibody that specifically binds Platelet Derived Growth Factor Receptor alpha, wherein the antibody comprises:
 (a) a variable heavy (VH) chain comprising the complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:2 and a variable light (VL) chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:4; or 
 (b) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:6 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:22; or 
 (c) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:6 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:8; or 
 (d) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:10 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:12; or 
 (e) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:18 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:20; or 
 (f) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:14 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:16. 
 
     
     
       2. An isolated vector comprising the nucleic acid molecule of  claim 1 . 
     
     
       3. A culture of host cells that comprise the vector of  claim 2 . 
     
     
       4. The isolated nucleic acid molecule of  claim 1  which encodes the antibody comprising:
 the VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:2 and the VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:4. 
 
     
     
       5. The isolated nucleic acid molecule of  claim 4  wherein the VH chain CDR1, CDR2, and CDR3 are encoded in the nucleotide sequence of SEQ ID NO:1 and the VL chain CDR1, CDR2, and CDR3 are encoded in the nucleotide sequence of SEQ ID NO:3. 
     
     
       6. An isolated vector comprising the nucleic acid of  claim 5 . 
     
     
       7. A culture of host cells that comprise the vector of  claim 6 . 
     
     
       8. An isolated vector comprising the nucleic acid of  claim 4 . 
     
     
       9. A culture of host cells that comprise the vector of  claim 8 . 
     
     
       10. The isolated nucleic acid molecule of  claim 1  which encodes the antibody comprising:
 the VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:10 and the VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:12. 
 
     
     
       11. The isolated nucleic acid molecule of  claim 10  wherein the encoded antibody comprises the VH chain of SEQ ID NO:10 and the VL chain of SEQ ID NO:12. 
     
     
       12. The isolated nucleic acid molecule of  claim 10  wherein the VH chain CDR1, CDR2, and CDR3 are encoded in the nucleotide sequence of SEQ ID NO:9 and the VL chain CDR1, CDR2, and CDR3 are encoded in the nucleotide sequence of SEQ ID NO:11. 
     
     
       13. The isolated nucleic acid molecule of  claim 12  wherein the VH chain is encoded by SEQ ID NO:9 and the VL chain is encoded by SEQ ID NO:11. 
     
     
       14. An isolated vector comprising the nucleic acid of  claim 12 . 
     
     
       15. A culture of host cells that comprise the vector of  claim 14 . 
     
     
       16. An isolated vector comprising the nucleic acid of  claim 13 . 
     
     
       17. A culture of host cells that comprise the vector of  claim 16 . 
     
     
       18. An isolated vector comprising the nucleic acid of  claim 10 . 
     
     
       19. A culture of host cells that comprise the vector of  claim 18 . 
     
     
       20. The isolated nucleic acid molecule of  claim 1  that encodes a single chain antibody. 
     
     
       21. A composition comprising a first isolated nucleic acid molecule encoding a variable light chain and a second isolated nucleic acid molecule encoding a variable heavy chain of an antibody that specifically binds Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha), wherein the antibody comprises:
 (a) a variable heavy (VH) chain comprising the complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:2 and a variable light (VL) chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:4; or 
 (b) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:6 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:22; or 
 (c) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:6 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:8; or 
 (d) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:10 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:12; or 
 (e) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:18 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:20; or 
 (f) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:14 and a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:16. 
 
     
     
       22. An isolated nucleic acid molecule encoding a variable light chain of an antibody that specifically binds Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha), wherein the antibody comprises:
 (a) a variable light (VL) chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:4; or 
 (b) a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO: 22; or 
 (c) a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:8; or 
 (d) a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:12; or 
 (e) a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:20; or 
 (f) a VL chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:16. 
 
     
     
       23. An isolated nucleic acid molecule encoding a variable heavy chain of an antibody that specifically binds Platelet Derived Growth Factor Receptor alpha (PDGFR-alpha), wherein the antibody comprises:
 a) a variable heavy (VH) chain comprising the complementarity determining region (CDR) 1, CDR2, and CDR3 of SEQ ID NO:2; or 
 (b) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:6; or 
 (c) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:10; or 
 (d) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:18; or 
 (e) a VH chain comprising the CDR1, CDR2, and CDR3 of SEQ ID NO:14.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.